Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
New England Journal of Medicine October 4, 2023 Andreas Reif, Istvan Bitter, Jozefien Buyze et al. 197 citations
BACKGROUND: In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low and the percentage with relapse is high. The efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine augmentation therapy, both in combination with...
DOI: 10.1056/nejmoa2304145 (opens in new tab)
Treatment-resistant depression
Major depressive disorder
Nasal spray
Clinical endpoint
+8